real peptides FAQ

Inject as early as your schedule allows, ideally still in a fasted state even if that's 9–10 AM. The critical factor is the fasted window. 12+ hours without food. Not the exact clock time. Delay your first meal until 60 minutes post-injection to preserve the metabolic advantage. If you must eat before injection (shift workers, early training sessions), prioritize protein-only meals (eggs, lean meat) that minimally affect insulin. Avoid carbohydrates within 2 hours of dosing. Our experience shows that fasted-state injection at 10 AM outperforms fed-state injection at 6 AM every time.

Reduce dose by 30–40% and split into smaller, more frequent administrations. While Selank is α2-selective, individual variation in GABA-A receptor subunit distribution means some users experience mild α1-mediated sedation during initial upregulation. This typically resolves by day 7–10 as receptor expression stabilizes. If sedation persists beyond 10 days at reduced dose, Selank may not be the optimal GABAergic modulator for your receptor profile.

You'll detect weaker prosocial effects or null results. By 60 minutes, plasma oxytocin has declined 40–50% from peak, and CNS receptor occupancy follows the same curve. Studies consistently show that behavioral tasks administered at 60+ minutes yield effect sizes 50–65% smaller than those at 40 minutes. If your protocol design requires flexibility in timing, build the testing window at 35–50 minutes. Not 'within 90 minutes of dosing'.

Maintain serum 25(OH)D at 40–60 ng/mL throughout the peptide protocol. Even if baseline vitamin D is adequate, seasonal variation, sun exposure changes, and metabolic shifts can reduce 25(OH)D by 10–15 ng/mL over 8–12 weeks. Vitamin D receptor expression in thymic tissue responds dynamically to circulating 25(OH)D. A drop from 50 ng/mL to 35 ng/mL reduces receptor density measurably. Research protocols examining immune optimization maintain consistent vitamin D3 dosing (4,000–6,000 IU daily) throughout peptide administration to prevent receptor downregulation. Test serum 25(OH)D at baseline and again at 8 weeks to confirm levels remain above 40 ng/mL.

Extend the protocol to 6–8 weeks and reduce BPC-157 frequency to every other day after week 4. Chronic tendinosis involves degenerative collagen with minimal active inflammation. The VEGF pathway remains relevant but receptor density is lower than acute injury states. TB-500 becomes the primary driver in chronic cases because cellular migration addresses scar tissue remodelling more directly than angiogenesis.

Verify peptide integrity first. Improper storage or reconstitution degrades DSIP within hours at room temperature. If peptide quality is confirmed, examine dosing timing: DSIP must be administered within 60–90 minutes of the target sleep phase. Studies show administration during the wrong circadian phase produces no measurable effect. Finally, confirm your measurement tool: actigraphy cannot detect delta wave changes. Polysomnography with EEG is required for publication-grade DSIP research.

Administer it anyway, but understand the limitation. VEGF receptor expression during the acute trauma phase (0–12 hours) is minimal. The inflammatory cascade hasn't fully activated receptor upregulation yet. You're not causing harm, but bioavailability is reduced compared to the 12–16 hour window. The peptide will still exert some angiogenic effect as receptor density increases over the next 24–48 hours.

Most thymalin used in clinical research was pharmaceutical-grade material produced under GMP conditions in Russia or Eastern Europe. The peptide sold by research suppliers varies in purity, synthesis method, and potency verification. Lyophilised thymalin should be reconstituted with bacteriostatic water and stored at 2–8°C after mixing. Temperature excursions above 8°C denature the peptide structure irreversibly. If the product arrived without a certificate of analysis (CoA) showing >98% purity via HPLC, you cannot verify it matches the material used in published trials. Our experience: sourcing peptides without third-party testing introduces significant quality variability that clinical results don't account for.

Discard the vial immediately. Cloudiness or visible particles indicate protein aggregation caused by temperature excursion, contamination, or improper reconstitution. Aggregated thymalin has significantly reduced bioavailability and may trigger localised immune reactions at the injection site. This typically occurs when bacteriostatic water is added too quickly (causing foaming) or when the vial is shaken instead of gently swirled. Properly reconstituted thymalin should be clear and colourless. If cloudiness appears 5–7 days after reconstitution despite refrigeration, bacterial contamination is the likely cause. Switch to a fresh vial and verify your bacteriostatic water hasn't expired.

SS-31 becomes the primary intervention. If cristae are disrupted, cardiolipin is oxidized, or cytochrome c is translocating to the cytosol, NAD+ supplementation alone won't restore function because the membrane architecture that houses the electron transport chain is compromised. This scenario is common in neurodegenerative disease models (Parkinson's, ALS), ischemic injury, and genetic mitochondrial disorders. SS-31 at 1–3 mg/kg in rodent models or 40 mg daily in human trials stabilizes the membrane first. Then, if needed, NAD+ precursors can be added to support biogenesis of new, protected mitochondria.

Stop the GH secretagogue before starting AOD-9604, or choose one pathway exclusively. MK 677 elevates endogenous growth hormone across all receptor types, which means adding AOD-9604 creates redundant beta-3 signalling without additional lipolytic benefit. The combination also increases the likelihood of elevated IGF-1 and insulin resistance. Outcomes AOD-9604 alone avoids. If your goal is selective fat loss without systemic GH effects, discontinue MK 677 for at least 7 days (five half-lives) before beginning the AOD-9604 protocol.

Administer both peptides in separate injections at different anatomical sites (e.g., Cartalax subcutaneous in the quadriceps, Epithalon subcutaneous in the abdomen) to avoid peptide-peptide interactions at the injection site. Stagger administration times by 4–6 hours minimum. Cartalax in the morning post-injury induction, Epithalon in the evening to align with circadian melatonin secretion patterns. No published studies document negative interactions between Cartalax and Epithalon, but separating administration eliminates the risk of competitive receptor binding or formulation incompatibility.

Verify with a calibrated digital thermometer placed inside the fridge (not on the door). Standard household fridges are calibrated for food safety (below 5°C) but fluctuate widely during normal use. Place the thermometer in the middle shelf toward the back. This is the most stable thermal zone. Check it after 24 hours. If the reading is above 8°C at any point, your peptides are degrading faster than the 28-day window assumes. Consider a dedicated laboratory mini-fridge with digital temperature logging or a medication cooler designed for insulin storage, which maintains tighter temperature control than standard appliances.

Clinical evidence for thymalin's immune effects is strongest in adults over 60 with measurable thymic involution. Younger adults (under 50) with normal thymic function show minimal or inconsistent responses in published trials. The mechanism depends on compensating for lost endogenous thymulin. If your thymus is still producing adequate levels, exogenous peptide administration offers little additional benefit. Research applications in younger populations focus on acute immune challenges (post-surgical recovery, chronic viral infections) rather than anti-aging per se.

This pattern indicates platelet-mediated interaction, not clotting factor inhibition. INR measures the extrinsic coagulation cascade (factors II, VII, X). It doesn't capture platelet function or nitric oxide effects. A normal INR with prolonged bleeding time means the peptide is affecting primary haemostasis (platelet plug formation) while warfarin affects secondary haemostasis (fibrin clot stabilisation). The solution is not warfarin dose reduction. That worsens thromboembolic risk without addressing platelet dysfunction. The correct intervention is peptide discontinuation or dose reduction, or switching to an anticoagulant without antiplatelet overlap (heparin instead of warfarin, for example).

Transient flushing and mild nausea are reported in 15–25% of users during the first 7–10 days of use and typically resolve as the body adapts to elevated NAD+ turnover. The mechanism is likely related to rapid methylation shifts and downstream effects on neurotransmitter metabolism. If symptoms are severe enough to disrupt daily function, reduce the dose to 25–50mg for 5–7 days, then re-escalate slowly. Persistent symptoms beyond two weeks or severe GI distress (vomiting, diarrhea) suggest reconstitution error or contamination. Verify your bacteriostatic water source and ensure sterile technique during mixing. Real Peptides provides detailed reconstitution protocols with every order to minimize user error.

Continue the protocol for at least 14 days before evaluating efficacy. BDNF upregulation is cumulative. Synaptic strengthening happens during sleep cycles over multiple nights, not within a single dose. Subjective memory improvement typically becomes apparent between days 5–10 as newly encoded information begins consolidating more efficiently. If no effect appears by day 14, dosing may be subthreshold (increase to 600 mcg split morning/midday) or baseline BDNF levels may already be optimised through other factors (regular aerobic exercise, adequate sleep).

Discard the vial immediately. Don't attempt to filter or use it. Visible particulate matter indicates peptide aggregation from pH incompatibility, temperature exposure, or contaminated bacteriostatic water. Aggregated peptides can't bind to receptors and may trigger localised inflammatory responses at injection sites. Reconstitute a fresh vial using verified bacteriostatic water (pH 5.5–6.5) and confirm the powder fully dissolves into a clear solution before any administration.

Yes. Inject 60 minutes before your single meal, not earlier. OMAD creates a 23-hour fasting window, which means GH receptors are maximally sensitised but cortisol may also be elevated. Injecting 90+ minutes before eating risks the GH pulse peaking and declining before you break your fast, wasting the nutrient partitioning benefit. The one-hour pre-meal window ensures GH peaks as insulin begins rising, synchronising anabolic signalling with amino acid availability.

This combination is common in longevity research protocols and mechanistically sound. Cartalax upregulates the genes that produce structural proteins; growth hormone secretagogues like MK 677 or CJC-1295 increase the anabolic signalling that drives protein synthesis from those upregulated genes. The two mechanisms complement rather than duplicate each other. Timing matters: administer Cartalax during the late rest phase to optimize transcriptional effects, then dose growth hormone secretagogues 30–60 minutes later to maximize the anabolic window.